Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 trial at Mayo Clinic evaluating low-dose selinexor in combination with choline salicylate for relapsed or refractory Hodgkin lymph…
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 study of ibrutinib in combination with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma has completed with re…
-
FDA approval · 2026-01-06FDA Approved: BORTEZOMIB — Original Application (Gland Pharma Limited)
FDA approved the original application for Bortezomib from Gland Pharma Limited as a generic injectable, covering indications established for…
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma [Phase 3]
A Phase 3 trial evaluating VMP with high-dose melphalan followed by VRD consolidation and lenalidomide maintenance in newly diagnosed multip…
-
CLINICAL_TRIALS withdrawal · 2026-01-06Clinical Trial Update: Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating immune reconstitution monitoring and pneumococcal vaccination in patients treated with CAR-T cells has be…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma. [Phase 2, Phase 3]
A multicenter prospective diagnostic study is evaluating 68Ga-BCMA PET/CT to target BCMA expression in multiple myeloma. The Phase 2/3 trial…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma [Phase 4]
A Phase 4 clinical trial is evaluating whether adding low-dose lenalidomide to ixazomib maintenance improves outcomes for high-risk multiple…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]
A Phase 1b study is evaluating talquetamab bridging therapy followed by cilta-cel in relapsed/refractory multiple myeloma; the trial is curr…
-
CLINICAL_TRIALS trial_result · 2026-01-05Clinical Trial Update: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy [Phase 3]
Phase 3 clinical trial comparing allogeneic stem cell transplantation versus conventional salvage therapy for relapsed or progressive multip…
-
CLINICAL_TRIALS trial_result · 2026-01-02Clinical Trial Update: Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma [NA]
This clinical trial update evaluates the impact of paramedical consultations on oncological supportive care for outpatients with multiple my…
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]
This document reports an early-phase 1 study of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone for relapsed/refractory…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) [Phase 2]
Phase 2 clinical trial evaluating minimal residual disease–driven deferral of transplant in dysproteinemia, including multiple myeloma and A…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)
A recruiting clinical study evaluating whether a pragmatic geriatric assessment before CAR-T cell therapy or bispecific antibody treatment c…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: A Dietary Study for People With Multiple Myeloma [NA]
An ongoing dietary-study trial for people with multiple myeloma is currently recruiting, sponsored by Memorial Sloan Kettering Cancer Center…
-
FDA approval · 2025-12-29FDA Approved: POMALIDOMIDE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Camber Pharmaceuticals’ pomalidomide, providing a generic version of pomalidomide under the …
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 2]
A Phase 2 study assessing subcutaneous isatuximab in combination with carfilzomib and dexamethasone for adults with relapsed/refractory mult…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma [NA]
A clinical trial update indicates that Nanjing Legend Biotech's LCAR-F33S is being studied for relapsed/refractory multiple myeloma and is c…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: Quality of Life Assessment of Caregivers of Patients With Multiple Myeloma [NA]
This clinical trial update describes a study evaluating the quality of life of caregivers of patients with multiple myeloma. The study statu…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies [NA]
This clinical trial compares reduced-dose apixaban and rivaroxaban against low-molecular-weight heparin for venous thromboembolism managemen…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Randomised Controlled Trial of Artificial Intelligence-assisted Health Education [NA]
A randomized controlled trial to assess the effectiveness of artificial intelligence–assisted health education, sponsored by Zhongnan Hospit…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma [Phase 1]
A Phase 1 trial evaluating three venetoclax-based regimens (Ven-Rd, Ven-Dd, Ven-DRd) in multiple myeloma. The study is currently recruiting …
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Prehabilitation Feasibility Among Older Adults Undergoing Transplantation [NA]
This clinical trial update reports ongoing recruitment for a feasibility study evaluating prehabilitation in older adults with multiple myel…
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: A Study of WVT078 in Patients With Multiple Myeloma (MM) [Phase 1]
A Phase 1 study of WVT078 in patients with multiple myeloma has been terminated.
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 [Phase 2]
Phase 2 clinical trial update for MajesTEC-5 in multiple myeloma, currently recruiting at University of Heidelberg Medical Center.
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stress (FOCUS) [NA]
This clinical trial update describes a telemedicine and mobile health symptom management intervention for advanced cancer patients (FOCUS), …